tbuckley/cabot-search huggingface dataset:
Combined associations of body weight and lifestyle factors with all cause and cause specific mortality in men and women: prospective cohort study
Authors: Nicola Veronese, Yanping Li, JoAnn E Manson, Walter C Willett, Luigi Fontana, Frank B Hu
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To evaluate the combined associations of diet, physical activity, moderate alcohol consumption, and smoking with body weight on risk of all cause and cause specific mortality. <b>Design</b>&nbsp;Longitudinal study with up to 32 years of follow-up. <b>Setting</b>&nbsp;Nurses' Health Study (1980-2012) and Health Professionals Follow-up Study (1986-2012). <b>Participants</b>&nbsp;74 582 women from the Nurses' Health Study and 39 284 men from the Health Professionals Follow-up Study who were free from cardiovascular disease and cancer at baseline. <b>Main outcome measures</b>&nbsp;Exposures included body mass index (BMI), score on the alternate healthy eating index, level of physical activity, smoking habits, and alcohol drinking while outcome was mortality (all cause, cardiovascular, cancer). Cox proportional hazard models were used to calculate the adjusted hazard ratios of all cause, cancer, and cardiovascular mortality with their 95% confidence intervals across categories of BMI, with 22.5-24.9 as the reference. <b>Results</b>&nbsp;During up to 32 years of follow-up, there were 30 013 deaths (including 10 808 from cancer and 7189 from cardiovascular disease). In each of the four categories of BMI studied (18.5-22.4, 22.5-24.9, 25-29.9, ≥30),&nbsp;people with one or more healthy lifestyle factors had a significantly lower risk of total, cardiovascular, and cancer mortality than individuals with no low risk lifestyle factors.&nbsp;A combination of at least three low risk lifestyle factors and BMI between 18.5-22.4 was associated with the lowest risk of all cause (hazard ratio 0.39, 95% confidence interval 0.35 to 0.43), cancer (0.40, 0.34 to 0.47), and cardiovascular (0.37, 0.29 to 0.46) mortality, compared with those with BMI between 22.5-24.9 and none of the four low risk lifestyle factors. <b>Conclusion</b>&nbsp;Although people with a higher BMI can have lower risk of premature mortality if they also have at least one low risk lifestyle factor, the lowest risk of premature mortality is in people in&nbsp;the 18.5-22.4&nbsp;BMI&nbsp;range with high score on the alternate healthy eating index, high level of physical activity, moderate alcohol drinking, and who do not smoke. It is important to consider diet and lifestyle factors in the evaluation of the association between BMI and mortality.
TRO40303 reduces mitochondrial injury and ameliorates experimental acute pancreatitis
Authors: M. Ahsan Javed, L. Wen, M. Awais, M. Chvanov, T. Bordet, M. Michaud, S. Schaller, R. Pruss, A. Tepikin, D. Criddle, R. Sutton
Journal: International Journal of Surgery (2016)
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112
Authors: Ilaria Iacobucci, Federica Cattina, Silvia Pomella, Annalisa Lonetti, Anna Ferrari, Cristina Papayannidis, Stefania Trino, Daniela Erriquez, Viviana Guadagnuolo, Emanuela Ottaviani, Serena Formica, Simona Soverini, Francesca Paoloni, Marco Vignetti, Domenico Russo, Giovanni Perini, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2011)
Thiocyanate-Dependent Inhibition of Spontaneous and Agonist-Induced Eosinophil Apoptosis by Eosinophil Peroxidase (EPO): A Potential Physiologic Role for Endogenously Generated HOSCN in Maintaining Eosinophil Viability.
Authors: Shawn A. Mahmud, Jianguo Wang, Arne Slungaard
Journal: Blood (2006)
Activating KIR (B Haplotype) in Unrelated Donors Improves Disease-Free Survival after HLA-Matched and Mismatched Allogeneic Transplantation for Acute Myeloid Leukemia: Implications for Donor Selection Using KIR Genotyping.
Authors: Sarah Cooley, Jeffrey S. Miller, Elizabeth Trachtenberg, Tracy Bergemann, Koy Saeteurn, John Klein, Lisbeth A. Guethlein, Steven G.E. Marsh, Daniel Geraghty, Peter Parham, Daniel Weisdorf
Journal: Blood (2007)
An Investigational Proteasome Inhibitor MLN9708 (MLN2238) Induces Apoptosis In Human Multiple Myeloma Cells In Vitro
Authors: Aisha Masood, Kasyapa Chitta, Kiersten M Miles, Nazmul H Khan, Remi Adelaiye, Drusilla Akhtar, Taimur Sher, Asher A. Chanan-Khan
Journal: Blood (2010)
Quantitative Molecular Expression of the Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia Cells as a Possible Marker for Minimal Residual Disease Detection.
Authors: Michela Aluigi, Antonio Curti, Emanuela Ottaviani, Giovanna Lucchetti, Valentina Salvestrini, Alessandra D’Addio, Sara Trabanelli, Francesca Fiore, Massimo Massaia, Giovanni Martinelli, Michele Baccarani, Roberto M. Lemoli
Journal: Blood (2007)
Molecular Responders (&lt;3-log Reduction) among CML Patients in Complete Cytogenetic Remission Show a Lower Number of BCR-ABL+ Hematopoietic Progenitors Compared to Non-Responders.
Authors: Adalberto Ibatici, Giusy Fugazza, Nadia Sessarego, Marina Podesta, Stefania Agliano, Sarah Pozzi, Mirko Corselli, Anna Garuti, Mario Sessarego, Francesco Frassoni
Journal: Blood (2005)
Management of mild hypertension in adults
Authors: Anthony J Viera, Emily M Hawes
Journal: BMJ (2016)

Elevated blood pressure is a common risk factor for cardiovascular disease and affects one in three adults. Blood pressure lowering drugs substantially reduce the risk of stroke, coronary heart disease, heart failure, and premature death, but most clinical trials showing benefits have primarily included patients with moderate to severe hypertension, known cardiovascular disease, or elevated risk of cardiovascular disease. The benefits of treating mild hypertension in patients without cardiovascular disease are less clear, but recent meta-analyses offer some insights. Pooled data from trials that include a large percentage of participants with mild hypertension show significant reductions in stroke, death from cardiovascular disease, and total mortality. Meta-analyses comparing lower blood pressure targets also suggest a benefit of treating patients with mild hypertension, although net benefits are greater for patients at higher absolute levels of cardiovascular disease risk. Before starting drug treatment, most patients should have out-of-office monitoring to confirm hypertension. Lifestyle modifications for reducing blood pressure are appropriate for all patients and may be recommended while delaying drug treatment for those at lower absolute levels of cardiovascular disease risk. Patient level control of blood pressure is supported by home monitoring and by once daily, low cost drug. Control of blood pressure for a population of patients is enhanced by system level interventions such as registries, implementation of evidence based protocols, drug titration visits, and performance metrics.
Coincidence of bcr/abl-Positive Chronic Myeloid Leukemia and bcr/abl-Negative Chronic Myeloproliferative Disorder and Its Relevance to the Course of Disease.
Authors: Guntram Buesche, Oliver Bock, Kais Hussein, Nils von Neuhoff, Brigitte Schlegelberger, Hans H. Kreipe
Journal: Blood (2007)
Insomnia heterogeneity: Characteristics to consider for data-driven multivariate subtyping
Authors: Jeroen S. Benjamins, Filippo Migliorati, Kim Dekker, Rick Wassing, Sarah Moens, Tessa F. Blanken, Bart H.W. te Lindert, Jeffrey Sjauw Mook, Eus J.W. Van Someren
Journal: Sleep Medicine Reviews (2016)

Meta-analyses and systematic reviews have reported surprisingly few consistent insomnia-characteristics with respect to cognitions, mood, traits, history of life events and family history. One interpretation of this limited consistency is that different subtypes of insomnia exist, each with its own specific multivariate profile of characteristics. Because previously unrecognized subtypes will be differentially represented in individual studies and dilute effect sizes of subtype-dependent characteristics of importance, they are unlikely to be reported consistently in individual studies, let alone in meta-analyses. This review therefore aims to complement meta-analyses by listing previously reported psychometric characteristics of insomnia, irrespective of the degree of consistency over studies. The review clearly indicates that characteristics of insomnia may not be limited to sleep. Reports suggest that at least some individuals with insomnia may deviate from people without sleep complaints with respect to demographics, mental and physical health, childhood trauma, life events, fatigue, sleepiness, hyperarousal, hyperactivity, other sleep disorders, lifetime sleep history, chronotype, depression, anxiety, mood, quality of life, personality, happiness, worry, rumination, self-consciousness, sensitivity, dysfunctional beliefs, self-conscious emotion regulation, coping, nocturnal mentation, wake resting-state mentation, physical activity, food intake, temperature perception and hedonic evaluation. The value of this list of characteristics is that 1) internet has now made it feasible to asses them all in a large sample of people suffering from insomnia, and 2) statistical methods like latent class analysis and community detection can utilize them for a truly bottom-up data-driven search for subtypes. The supplement to this review provides a blueprint of this multivariate approach as implemented in the Sleep registry platform (www.sleepregistry.nl), that allows for bottom-up subtyping and fosters cross-cultural comparison and worldwide collaboration on insomnia subtype finding - and beyond.
AB0339 Correlation between Clinical and Anti-Destructive Effects of Rituximab (RTM) and B-Cells Count in Rheumatoid Arthritis (RA) Patients
Authors: A.V. Pivanova, G. Lukina, Y. Sigidin, A.V. Smirnov, K.Kh. Kuzikyants, A.Yu. Kuznetsova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis is a chronic autoimmune disease characterized by inflammation of the synovial tissue and destruction of the cartilage and bone. Antirheumatic treatment plays a important role in controlling the inflammation of rheumatoid arthritis and in minimizing joint damage. Rituximab has been successfully used to treat rheumatoid arthritis. It is a chimeric monoclonal antibody that targets the CD20 molecule expressed on the surface of B cells. Noteworhty, clinical and antidestructive effects often did not coincide. <h3>Objectives</h3> To study the impact of B-cells depleting therapy (RTM) on joint destruction in correlation with clinical effects and B-cells counts. <h3>Methods</h3> The study included 61 RA pts (average disease duration 10,1±7,7 y., mean DAS28 6,3±0,94, RF-positive 87%, ACCP–positive 93%) undergoing RTM therapy. Clinical effect was scored by EULAR criteria, radiographic progression was assessed using Sharp/van der Heijde (SvH) modified scoring method. B-cell level was measured with flow cytometry. <h3>Results</h3> By Week 48 after 2 RTM courses good response was documented in 29,7% pts, good and satisfactory in 85,3%; remission was achieved in 14,6% pts. There was no radiographic progression in remission pts., in 83% of pts with low disease activity and in 33% - with moderate disease activity. Of note, further progression in joint space narrowing was more pronounced than bony tissue destruction - in 32% and 25%m respectively. Clinical and anti-destructive effects were often dis-matching: bone destruction was abrogated without any clinical improvement in 54% of pts. There was no significant difference in clinical effects of RTM dosing regimens (1000mg x2 or 500mg x2). More potent anti-destructive effect was documented in pts getting higher RTM dose values. No significant influence of B-cells depletion on radiographic progression of the disease was noticed. Although, in RA pts achieving remission B-cell depletion was more notable (Median, IQR 0% (0–1.133) as compared to pts with active disease (Median, IQR 0.8% (0.2–4.8, p 0.001). <h3>Conclusions</h3> Clinical and anti-destructive effects of B-cell depletion therapy are not always equivalent. Therapeutic effect of two dosing regimens was similar, but the anti-destructive one was more pronounced with higher RTM doses. Radiographic progression did not show any correlation with the degree of B-cells depletion. Most pronounced B-cells depletion was documented in pts achieving remission. <h3>Disclosure of Interest</h3> None declared
Re: Marcus G. Cumberbatch, Matteo Rota, James W.F. Catto, Carlo La Vecchia. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol 2016;70:458–66
Authors: Roman Sosnowski, Paolo Verze, Cosimo De Nunzio, Marc A. Bjurlin
Journal: European Urology (2015)
Examination of Genetic Aberrations in Chlamydophila Psittaci negative MALT Lymphomas of the Ocular Adnexa
Authors: Daxing Zhu, Offiong F Ikpatt, Sander R Dubovy, Yasodha Natkunam, Jennifer R Chapman-Fredricks, Yao-Shan Fan, Izidore S Lossos
Journal: Blood (2012)
A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors
Authors: François Guilhot, Viviane Dubruille, Aleksander B. Skotnicki, Andrey Hellmann, Jila Shamsazar, Priscille M. Bourquelot, Muhammad Jalaluddin, Martha Li, Elisabetta Abruzzese, Luke Akard
Journal: Blood (2008)
Conception and Pregnancy in Patients (pts) with Chronic Myeloid Leukemia (CML) Receiving Therapy with Imatinib Mesylate (IM).
Authors: Pat Ault, Hagop Kantarjian, Susan O’Brien, Charles Koller, Stefan Faderl, Emil J. Freireich, Mary Beth Rios, Jorge Cortes
Journal: Blood (2005)
Do Apollo Astronaut Deaths Shine a Light on Deep Space Radiation and Cardiovascular Disease?
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SP0142 How To Select The Most Appropriate Capillaroscopic Device: Pros and Cons
Authors: F. Ingegnoli
Journal: Annals of the Rheumatic Diseases (2016)

Nailfold capillaroscopy is a noninvasive technique that allows direct observation of capillaries using a magnification lens for the two-dimensional projection of the three-dimensional capillary network. After application of a drop of immersion oil, capillaries can be observed with a magnification lens because they run parallel to the epidermis at the nailfold area. A number of different instruments are available to perform the exam. They have different characteristics in terms of their cost, quality of images, magnifications, training period, software for image analysis and storage. Some of these instruments can be used both in clinical and research settings such as the stereomicroscope and the videocapillaroscope. The stereomicroscope allows the widefield visualization of the nailfold with low magnifications, the training is relatively short, but the examination is difficult to perform in patients with digital contractures. There appears to be consensus regarding the use of videocapillaroscopy that allows a detailed visualisation of capillary morphology using higher magnifications (100–300x). Contact probe with polarized light microscopy permits easier observation of the skin surface, and the training period is briefer. Specific softwares are available for images analysis, storage, and complete medical reports (text + images) can be produced. By contrast, in a clinical setting, nailfold capillaries can generally be visualised using more simple but also efficient tools such as a dermatoscope, USB microscope, ophtamloscope or smartphone device. The quality of images can be quite good, although the lower magnification means that some details are unlikely to be seen, and they often lack the possibility of image storage and measurement. <h3>Disclosure of Interest</h3> None declared
SP0059 Scoring Large Vessel Vasculitis
Authors: A.P. Diamantopoulos
Journal: Annals of the Rheumatic Diseases (2016)

Giant cell arteritis (GCA) and Takayasu9s arteritis are the two main forms of large vessel vasculitides (LVV) predominantly affecting the large and medium vessels. GCA is the most common form of systemic vasculitis. Studies have shown that ultrasound yields a high sensitivity and specificity in the diagnostics of GCA, and that it could also be useful as follow up tool. In coronary syndromes, the presence of increased carotid intima–media thickness (IMT) and plaques in the carotid or femoral arteries have been correlated with classic risk factors and coronary risk. Yet, in LVV, no studies exist regarding increased IMT due to vasculitis and its influence on disease activity and prognosis. Possible explanations include the lack of definitions on angiopathology, technique standardization and of a widely acknowledged scoring system. Recently, an OMERACT group on ultrasound in LVV introduced definitions on both vasculitic lesions and atherosclerosis. This session aims to present: 1. An overview and demonstration of the ultrasonographic definitions of vasculitis, 2. Considerations around potential scoring systems. <h3>Disclosure of Interest</h3> None declared
AB0362 Serum Lipid Level Changes Associated with Tocilizumab Treatment: Our Experience in Two University Hospitals:
Authors: B. García-Núñez, S. Lόpez-Salguero, F. Sivera, M. Andrés
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tocilizumab (TCZ) is a humanised monoclonal antibody against the Interleukin-6 (IL-6) receptor effective in patients with rheumatoid arthritis (RA) with an inadequate response to conventional DMARDs or an anti-TNF biologic. Among its side effects, a change in the serum lipid profile due to an increase of low density lipoproteins (LDLc) and of high density lipoproteins (HDLc) has been previously described. Its impact and proper management is still uncertain. <h3>Objectives</h3> To analyze the changes in serum lipid levels in patients under TCZ treatment. <h3>Methods</h3> Retrospective review. Patients treated with TCZ and complete serum lipid profile (total cholesterol, LDLc, HDLc, triglycerides) in two different rheumatology units were selected. Three time-points were established: 1) baseline; 2) one month after the start of TCZ; 3) six monthts after the start of TCZ. Epidemiologic and clinical data on al patients and laboratory findings (C reactive protein – CRP, erythrocyte sedimentation rate – ESR) at the given time-points were also recorded. A before-after comparative anlaysis using Wilcoxon9s test, an a correlational analysis with inflammation laboratory parameters using Spearman9s Rho test were performed. <h3>Results</h3> Thirty-five patients were included: 34 patients with rheumatoid arthritis and one with idiopathic retroperitoneal fibrosis. Patients were a mean (p25–75) of 57.5 years (51.8–63.3) old, and 30 (86%) were women. Table 1 shows the variations in lipid parameters at the different timepoints. A mild increase in HDLc levels was observed after one month of treatment which was maintained at 6 months later, but with no statistical significance (p=0.36). A significant elevation was observed in the remaining lipid paramenters (total cholesterol, LDLc, triglycerides) after one month of treatment, which dissapeared after 6 months of treatment. Inflammatory markers decreased significantly and persistently after the beginnig of TCZ treatment. In the correlation analysis no association was found between lipid levels and inflammatory markers (p&gt;0.05 for all comparisons). <h3>Conclusions</h3> With TCZ, most lipid parameters show a significant but transitory increase. A mild though non-significant increase in HDLc levels was also observed. The antiatherogenic benefit of TCZ might be mediated by qualitative changes in the HDLc molecule. Prospective and larger studies are needed to characterize these results better. <h3>Disclosure of Interest</h3> None declared
Impact of New Therapies On the Survival of Elderly (≥75 Years of Age) Previously Untreated Patients with Multiple Myeloma in a Community Hospital
Authors: Romany Johnpulle, Simran Sindhu, Lynn Nichols, Lynda Dimitroff, Mehul Patel, Peter Kouides, Pradyumna D. Phatak, Ronald L. Sham, Saad Jamshed
Journal: Blood (2012)
SP0188 Multiple Imputation: A Possible Solution To The Problem of Missing Data
Authors: J.C. Sergeant
Journal: Annals of the Rheumatic Diseases (2016)

Multiple imputation (MI) is a statistical technique that can be used to handle the problem of missing data. MI enables the use of all the available data without throwing any away and can avoid the bias and unrealistic estimates of uncertainty associated with other methods for handling missing data. In MI, the missing values in the data are filled in or “imputed” by sampling from distributions observed in the available data. This sampling is done multiple times, resulting in multiple datasets. Each of the multiple datasets is analysed and the results are combined to give overall results which reflect the uncertainty about the values of the missing data. This talk will explore what MI is, when it can be used and how to use it. The content will be accessible to a wide audience and illustrated with clear examples. <h3>Disclosure of Interest</h3> None declared
Mutant CCL2 protein coating mitigates wear particle-induced bone loss in a murine continuous polyethylene infusion model
Authors: Akira Nabeshima, Jukka Pajarinen, Tzu-hua Lin, Xinyi Jiang, Emmanuel Gibon, Luis A. Córdova, Florence Loi, Laura Lu, Eemeli Jämsen, Kensuke Egashira, Fan Yang, Zhenyu Yao, Stuart B. Goodman
Journal: Biomaterials (2016)
Acute Myeloid Leukemia with Normal Karyotype: Analysis of FLT3, NPM1, MLL and CEBPA Gene Abnormalities.
Authors: Fernanda Trigo, Fatima Torres, Patricia Guimaraes, Pedro Silva-Coelho, Ines Carvalhais, Ana Espirito Santo, Teresa Melo, Miriam Castro, Alexandra Fernandes, Purificacao Tavares, Jose E. Guimaraes
Journal: Blood (2007)
Long-Term Follow-Up Results of Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL)-The Vancouver Experience.
Authors: Yasser R. Abou Mourad, Stephen H. Nantel, Cynthia L. Toze, Thomas J. Nevill, Michael J. Barnett, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, John D. Shepherd, Heather J. Sutherland, Clayton A. Smith, Kevin W. Song
Journal: Blood (2005)